NPM1 and acute myeloid leukemia: Recently, a second-generation imiqualine, EAPB02303, has shown 200-fold greater potency and broader activity across AML subtypes, exhibiting selective efficacy against NPM1-mutated AML, making it a promising candidate for further clinical evaluation [167].